Abstract
Several clinical courses have been defined in multiple sclerosis (MS), but uncertainty remains as to whether they reflect different neuropathological mechanisms. Two recent concepts have emerged which could influence the treatment strategy adopted in MS: inflammation drives axonal damage; disability progression in MS follows a two-stage process.
Copyright © 2010 Elsevier B.V. All rights reserved.
MeSH terms
-
Adult
-
Alemtuzumab
-
Antibodies, Monoclonal / therapeutic use*
-
Antibodies, Monoclonal, Humanized
-
Antibodies, Neoplasm / therapeutic use*
-
Disability Evaluation
-
Disease Progression
-
Female
-
Humans
-
Immunologic Factors / therapeutic use*
-
Interferon beta-1b
-
Interferon-beta / therapeutic use*
-
Longitudinal Studies
-
Male
-
Middle Aged
-
Multiple Sclerosis / complications
-
Multiple Sclerosis / epidemiology
-
Multiple Sclerosis / immunology
-
Multiple Sclerosis / therapy*
-
Young Adult
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Antibodies, Neoplasm
-
Immunologic Factors
-
Interferon beta-1b
-
Alemtuzumab
-
Interferon-beta